A phase Ib study of combined VEGFR and mTOR inhibition with Vatalanib and everolimus in patients with advanced renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 12, Issue 4, 2014, Pages 241-250

  Bitting, Rhonda L ^a   Healy, Patrick ^a   Creel, Patricia A ^a   Turnbull, James ^a   Morris, Karla ^a   Wood, Sarah Yenser ^a   Hurwitz, Herbert I ^a   Starr, Mark D ^a   Nixon, Andrew B ^a   Armstrong, Andrew J ^a   George, Daniel J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical trial; mTOR inhibitor; Renal cell carcinoma; VEGFR inhibitor

Indexed keywords

ALKALINE PHOSPHATASE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; VASCULOTROPIN; VATALANIB; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PHTHALAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANUS CANCER; AREA UNDER THE CURVE; ASTHENIA; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; COLON CANCER; CONFERENCE PAPER; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEMALE; FOOT PAIN; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTION; KIDNEY CARCINOMA; LEUKOENCEPHALOPATHY; LUNG CANCER; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, RENAL CELL; CLINICAL TRIAL; FOLLOW UP; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PHTHALAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES;

EID: 84904743401     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.11.020     Document Type: Conference Paper

References (57)

1. H. Hurwitz, L. Fehrenbacher, and W. Novotny et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
2. H.J. Burstein, A.D. Elias, and H.S. Rugo et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 2008 1810 1816
3. K. Miller, M. Wang, and J. Gralow et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
4. K.D. Miller, L.I. Chap, and F.A. Holmes et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 2005 792 799
5. A. Sandler, R. Gray, and M.C. Perry et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
6. M.A. Socinski, S. Novello, and J.R. Brahmer et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 2008 650 656
7. J.M. Llovet, S. Ricci, and V. Mazzaferro et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
8. S.A. Wells Jr., B.G. Robinson, and R.F. Gagel et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J Clin Oncol 30 2012 134 141
9. B. Escudier, T. Eisen, and W.M. Stadler et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
10. B. Escudier, A. Pluzanska, and P. Koralewski et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
11. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
12. A. Desjardins, D.A. Reardon, and J.E. Herndon 2nd et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas Clin Cancer Res 14 2008 7068 7073
13. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
14. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62
15. N. Ferrara, K.J. Hillan, and H.P. Gerber et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400
16. E. Van Cutsem, J. Tabernero, and R. Lakomy et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 2012 3499 3506
17. C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
18. B.I. Rini, B. Escudier, and P. Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
19. A. Grothey, E. Van Cutsem, and A. Sobrero et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
20. J. Drevs, I. Hofmann, and H. Hugenschmidt et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model Cancer Res 60 2000 4819 4824
21. B. Morgan, A.L. Thomas, and J. Drevs et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol 21 2003 3955 3964
22. A.L. Thomas, B. Morgan, and M.A. Horsfield et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer J Clin Oncol 23 2005 4162 4171
23. S.F. Jones, D.R. Spigel, and D.A. Yardley 3rd et al. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies Clin Adv Hematol Oncol 9 2011 845 852
24. D. Spigel, S. Jones, and J. Hainsworth et al. A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies Cancer Invest 29 2011 308 312
25. C. de Bazelaire, D.C. Alsop, and D. George et al. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma Clin Cancer Res 14 2008 5548 5554
26. J.R. Hecht, T. Trarbach, and J.D. Hainsworth et al. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma J Clin Oncol 29 2011 1997 2003
27. E. Van Cutsem, E. Bajetta, and J. Valle et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma J Clin Oncol 29 2011 2004 2010
28. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22
29. P. Baldo, S. Cecco, and E. Giacomin et al. mTOR pathway and mTOR inhibitors as agents for cancer therapy Curr Cancer Drug Targets 8 2008 647 665
30. G.V. Thomas, C. Tran, and I.K. Mellinghoff et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer Nat Med 12 2006 122 127
31. G. Hudes, M. Carducci, and P. Tomczak et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
32. J.A. Garcia, and D. Danielpour Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies Mol Cancer Ther 7 2008 1347 1354
33. R.J. Motzer, B. Escudier, and S. Oudard et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
34. J. Baselga, M. Campone, and M. Piccart et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
35. J.C. Yao, M.H. Shah, and T. Ito et al. Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
36. D.A. Krueger, M.M. Care, and K. Holland et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis N Engl J Med 363 2010 1801 1811
37. H.A. Lane, J.M. Wood, and P.M. McSheehy et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor Clin Cancer Res 15 2009 1612 1622
38. T. O'Reilly, H.A. Lane, and J.M. Wood et al. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model Cancer Chemother Pharmacol 67 2011 193 200
39. W.Y. Kim, and W.G. Kaelin Jr. Molecular pathways in renal cell carcinoma - rationale for targeted treatment Semin Oncol 33 2006 588 595
40. A. Jaeger-Lansky, D. Cejka, and L. Ying et al. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo Cancer Biol Ther 9 2010 919 927
41. R.T. Abraham mTOR as a positive regulator of tumor cell responses to hypoxia Curr Top Microbiol Immunol 279 2004 299 319
42. A.M. Arsham, J.J. Howell, and M.C. Simon A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets J Biol Chem 278 2003 29655 29660
43. R. Humar, F.N. Kiefer, and H. Berns et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling FASEB J 2002 771 780
44. C. Treins, S. Giorgetti-Peraldi, and S. Murdaca et al. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway J Biol Chem 277 2002 27975 27981
45. W. Zundel, C. Schindler, and D. Haas-Kogan et al. Loss of PTEN facilitates HIF-1-mediated gene expression Genes Dev 14 2000 391 393
46. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
47. A. O'Donnell, S. Faivre, and H.A. Burris 3rd et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 2008 1588 1595
48. A.L. Thomas, T. Trarbach, and C. Bartel et al. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer Ann Oncol 18 2007 782 788
49. P.H. Patel, P.L. Senico, and R.E. Curiel et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma Clin Genitourin Cancer 7 2009 24 27
50. J. Sosman, and I. Puzanov Combination targeted therapy in advanced renal cell carcinoma Cancer 115 2009 2368 2375
51. J.D. Hainsworth, D.R. Spigel, and H.A. Burris 3rd et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma J Clin Oncol 28 2010 2131 2136
52. A.L. Harzstark, E.J. Small, and V.K. Weinberg et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma Cancer 117 2011 4194 4200
53. M. Fouladi, F. Laningham, and J. Wu et al. Phase I study of everolimus in pediatric patients with refractory solid tumors J Clin Oncol 25 2007 4806 4812
54. A. Boulay, S. Zumstein-Mecker, and C. Stephan et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells Cancer Res 64 2004 252 261
55. A.J. Armstrong, G.J. Netto, and M.A. Rudek et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer Clin Cancer Res 16 2010 3057 3066
56. A.J. Armstrong, D.J. George, and S. Halabi Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin J Clin Oncol 30 2012 3402 3407
57. M.I. Koukourakis, A. Giatromanolaki, and E. Sivridis et al. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy Clin Cancer Res 17 2011 4892 4900